• Real-world impact of nirmatrelvir plus ritonavir on SARS-CoV-2 infection

    1 day ago - By Healio

    As the COVID-19 pandemic heads into its 4th year, it is a good time to reflect on strides made for those with mild-to-moderate disease not requiring hospitalization.
    The first treatment for this population became available in late 2020 with the emergency use authorization of the first monoclonal antibody, bamlanivimab, followed by four EUAs for other monoclonal antibodies.
    Unfortunately, all the EUAs for treatment monoclonals were revoked because of a loss of activity against circulating variants. The remdesivir label now includes a 3-day course for this population, but it is logistically
    Read more ...